Key facts
- It has raised $59.7M across 3 recorded rounds; the latest was Early Stage VC ($11.3M) in Jan 2022.
- Notable investors include Impact Assets, Mission BioCapital, Dubin & Co., Cobro Ventures, Intel Ignite — 8 tracked in total.
- AI Proteins has filed 3 Form Ds with the SEC since 2022, most recently Apr 2024 ($5.0M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for AI Proteins
Funding rounds
3 roundsAbout AI Proteins
Operator of protein engineering technology intended to create novel therapeutic proteins for medical applications. The company offers AI-based protein design and a high-throughput discovery platform that generates synthetic proteins with optimized activity and stability, enabling pharmaceutical developers to access durable and targeted proteins suitable for diverse treatment approaches.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2021
- Employees
- 32
- Website
- aiproteins.com/
- Ownership
- Privately Held (backing)
AI Proteins doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AI Proteins shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AI Proteins in its N-PORT filings yet. We sweep new filings monthly.